BCR-ABL Transcripts - CML - Chronic Myeloid Leukemia
PUBLICATIONS
Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
November 2017, Clinical Lymphoma Myeloma & Leukemia
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
2017, Haematologica
Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients
December 2016, International journal of laboratory hematology
Characterization of the Different BCR-ABL Transcripts with a Single Multiplex RT-PCR
November 2004, Journal of Molecular Diagnostics
Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
November 2017, Clinical Lymphoma Myeloma & Leukemia
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
2017, Haematologica
Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients
December 2016, International journal of laboratory hematology
Characterization of the Different BCR-ABL Transcripts with a Single Multiplex RT-PCR
November 2004, Journal of Molecular Diagnostics
ARTICLES
Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
February 28, 2019, Cancer Therapy Advisor
BCR-ABL Transcript Type Predicts Response and Survival Among Patients with CML
February 1, 2016, ASH Clinical News
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
May 6, 2014, Leukemia
Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring
July 2, 2012, Hindawi
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
November 19, 2010, BMC Hematology
Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
February 28, 2019, Cancer Therapy Advisor
BCR-ABL Transcript Type Predicts Response and Survival Among Patients with CML
February 1, 2016, ASH Clinical News
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
May 6, 2014, Leukemia
Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring
July 2, 2012, Hindawi
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
November 19, 2010, BMC Hematology
